Current Report Filing (8-k)
May 15 2019 - 6:04AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
May
15
, 2019
Date
of Report (Date of earliest event reported)
Immune
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Florida
|
|
000-54933
|
|
59-3226705
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.
|
37
North Orange Ave, Suite 800M, Orlando, FL
|
|
32801
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
888-613-8802
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01. Other Events
Immune Therapeutics, Inc., a Florida corporation
(the “Company”), sent a Proxy Statement on Schedule 14A to shareholders of the Company on or around April 29,
2019 (the “Proxy Statement”). Since sending the Proxy Statement, the Company has received several questions from its
shareholders requesting additional information and clarification. The Company has elected to address the questions
posed by shareholders using this Current Report filed on Form 8-K (the “Current Report”) rather than respond to each
shareholder individually. The letter attached hereto as Exhibit 10.1 (the “Letter to Shareholders”) more thoroughly
explains the purpose for the Proxy Statement and how the Company intends to operate going forward.
Forward-
Looking Statements
Statements
contained in this Current Report and the Letter to Shareholders that are not statements of historical fact are intended to be
and are hereby identified as “forward-looking statements” for purposes of the safe harbor provided by the Private
Securities Litigation Reform Act of 1995. Generally, forward-looking statements include expressed expectations of future events
and the assumptions on which the expressed expectations are based. All forward-looking statements are inherently uncertain as
they are based on various expectations and assumptions concerning future events and they are subject to numerous known and unknown
risks and uncertainties which could cause actual events or results to differ materially from those projected. The Company undertakes
no obligation to update or revise this Current Report or the Letter to Shareholders to reflect future developments except as otherwise
required by the Securities Exchange Act of 1934.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits. The following exhibits are filed herewith.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IMMUNE
THERAPEUTICS, INC.
|
|
|
|
Date:
May 15, 2019
|
By:
|
/s/
Noreen Griffin
|
|
|
Noreen
Griffin, CEO
|
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Apr 2023 to Apr 2024